Advanced Lung Non-Small Cell Carcinoma

Oncology·MeSH: Lung Neoplasms

6 drugs in development·3 companies·4 clinical trials

Drug Pipeline by Phase

Phase 3(2)

Drug	Company
Cemiplimab	ENANTA PHARMACEUTICALS INC (ENTA)
ramucirumab	GH Research PLC (GHRS)

Phase 2(2)

Drug	Company
Cemiplimab	Assertio Holdings, Inc. (ASRT)
Diclofenac Potassium	ENANTA PHARMACEUTICALS INC (ENTA)

Phase 2/Phase 3(1)

Drug	Company
nogapendekin alfa	GH Research PLC (GHRS)

Phase 4(1)

Drug	Company
Diclofenac Potassium	Assertio Holdings, Inc. (ASRT)

BioSniper tracks 6 drugs in development for Advanced Lung Non-Small Cell Carcinoma across 3 companies.

There are 4 clinical trials targeting Advanced Lung Non-Small Cell Carcinoma tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.